Concise Prescribing Info
Dosage/Direction for Use
Adult : PO As tab: Initial: 2 g 1-2 times daily, increase by 2 g 1-2 times daily at 1-2 mth intervals. Maintenance: 2-16 g/day in 1 or 2 divided doses. As granules for susp: 5 g 1-2 times daily, increase in 5-g increments at intervals of 1 mth. Max: 30 g/day in 1-2 divided doses.
Dosage Details
Adult: As tab: Initially, 2 g 1-2 times daily, increase by 2 g 1-2 times daily at 1-2 mth intervals. Maintenance: 2-16 g daily in 1 or divided doses. As granules for susp: Initially, 5 g 1-2 times daily, increased in 5-g increments at intervals of 1 mth. Max: 30 g daily in 1-2 divided doses.
Mix contents of sachet to at least 100 mL of water or other suitable liquid (e.g. fruit juice, skimmed milk, non-carbonated beverage). Alternatively, it can be mixed w/ soups, cereals, pulpy fruits w/ a higher water content or yoghurt.
Special Precautions
Patient w/ GI dysfunction (e.g. constipation), phenylketonuria, limited thyroid reserve. Pregnancy and lactation.
Adverse Reactions
Constipation, faecal impaction, aggravation of haemorrhoids, abdominal discomfort (e.g. pain, cramping, distention), heartburn, flatulence, nausea, vomiting, diarrhoea, bloating, belching, indigestion, blood in stool; headache, migraine headache, sinus headache, dizziness, light-headedness, insomnia, anxiety, vertigo, drowsiness; rash, urticaria, dermatitis, muscle and joint pain, arthritis, backache, anorexia, fatigue, weakness, shortness of breath, swelling of the hands or feet; increased bleeding tendency (chronic use), hyperchloremic acidosis, transient and modest increases in serum AST, serum ALT and alkaline phosphatase concentrations.
Determine serum cholesterol and triglyceride concentrations prior to and regularly during therapy.
Symptoms: GI obstruction. Management: Dependent on the degree and location of obstruction and GI motility. Expert opinion is required.
Drug Interactions
May interfere w/ absorption of folic acid, oral phosphate supplements, and fats, preventing absorption of fat-soluble vit. Decreased absorption of tetracycline, penicillin G, hydrochlorothiazide, furosemide or gemfibrozil. May bind digoxin in the GI tract and impair its absorption. Decreased and/or delayed GI absorption of propranolol. May decrease serum concentration of mycophenolic acid.
Description: Colestipol binds w/ bile acids in the intestine to form an insoluble complex which is excreted in faeces, resulting in increased faecal loss of bile acid-bound LDL cholesterol.
Absorption: Not absorbed.
Excretion: Via faeces.
Chemical Structure

Click on icon to see table/diagram/image
Store between 20-25°C.
Disclaimer: This information is independently developed by MIMS based on Colestipol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in